Tomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter @TomiKilgore.
Shares of Aldeyra Therapeutics Inc.
plummeted 61.9% toward a 3 1/2-year low in very active morning trading Monday, enough to pace the Nasdaq’s decliners, after the Massachusetts-based biotechnology company said the U.S. Food and Drug Administration identified “substantive review issues” with the new dug application for its dry-eye disease treatment reproxalap. Trading volume ballooned to 12.3 million shares, compared with the full-day average of about 566,000 shares.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
FDA plans to propose ban on hair-straightening chemical products linked to health risksThe U.S. Food and Drug Administration is planning to propose a ban on certain hair-straightening products, such as chemical relaxers and pressing products.
Weiterlesen »
A brain atlas: Ambitious research may yield new understanding about dementiaExamining the human brain at the cellular level in more detail than ever before, scientists have identified an enormous array of cell types — more than 3,300 — populating our most complex organ, creating an atlas that may help pinpoint the cellular basis of neurological diseases and facilitate new therapeutics.
Weiterlesen »
Week 7 Trades: Stock Up, Stock DownWhile Travis Etienne has been a hot fantasy commodity, a trio of prized receivers are causing stress.
Weiterlesen »
1 Stock to Buy, 1 Stock to Sell This Week: Lululemon, PfizerStocks Analysis by Investing.com (Jesse Cohen) covering: Pfizer Inc, Lululemon Athletica Inc. Read Investing.com (Jesse Cohen)'s latest article on Investing.com
Weiterlesen »
Netflix Earnings Preview: Analysts Cut Stock Price Targets in ResetThe sentiment from analysts heading into the third-quarter results on Oct. 18 is that expectations may have become a bit too exuberant amid a slow advertising ramp-up and possible increased spending on licensed content.
Weiterlesen »
Learn stocks by tracking them with this sub, available for an extra $20 off through 10/15Save on stock tips with Tykr!
Weiterlesen »